The FDA has placed a partial clinical hold on Inovio Pharmaceuticals' (NASDAQ:INO) Phase 2/3 clinical trial of COVID-19 vaccine candidate INO-4800 and the Cellectra 2000 delivery device.
The agency cites the need to address additional questions about the study. The company says it plans to submit its response next month.
A partial clinical hold suspends enrollment but allows current participants to continue treatment.
The company's Phase 1 trial is not affected.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.